SureTrader SureTrader
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board:
Last Post: 5/28/2015 12:37:00 AM - Followers: 1225 - Board type: Free - Posts Today: 2
PostSubject
#191741  Sticky Note JUNO > CAR-T powerhouse Juno allies with gene-editing biocqr 05/27/15 10:07:18 AM
#191735  Sticky Note GBIM -60% PM on failure of phase-2 HBV DewDiligence 05/27/15 09:02:25 AM
#191734  Sticky Note RTRX sells priority voucher zipjet 05/27/15 08:19:21 AM
#191728  Sticky Note Express Scripts Holding Co., a large manager of jbog 05/26/15 08:35:17 PM
#191727  Sticky Note AbbVie Presents New Data for its Investigational Hepatitis jbog 05/26/15 07:32:48 PM
#191527  Sticky Note LTPN -78% on failure of AMD program: DewDiligence 05/20/15 10:28:36 AM
#191781   >> how much we can trust it given jq1234 05/28/15 12:37:00 AM
#191780   (1) "Are their scrips leveling off as you say?" Rocky3 05/28/15 12:01:15 AM
#191779   Dew, I like it when a meltdown day vinmantoo 05/27/15 11:32:56 PM
#191778   So what do you think hosting a round vinmantoo 05/27/15 11:28:07 PM
#191777   SPHS $1.08 + $.20 has room to run jaybird249 05/27/15 10:00:28 PM
#191776   Viberzi (eluxadoline) biotech jim 05/27/15 09:16:48 PM
#191775   Seres S-1: http://www.sec.gov/Archives/edgar/data/1609809/000119312515202059/d81 mcbio 05/27/15 09:05:42 PM
#191774   Washington Post: Northwest Bio stock woes highlight mr_o 05/27/15 08:44:41 PM
#191773   GBIM -60% PM on failure of phase-2 HBV mcbio 05/27/15 08:37:00 PM
#191772   Does Fibrocell have one, I didn't see anything mr_o 05/27/15 08:36:52 PM
#191771   can't remember which cocky poster here was trashing honestabe13 05/27/15 08:27:02 PM
#191770   Anyone have an opinion on tpiv? Seems interesting. ronpopeil 05/27/15 08:09:32 PM
#191769   VRX (SLXP) and ACT PRs on today’s FDA approvals: DewDiligence 05/27/15 06:35:20 PM
#191768   GILD's investments in new Canadian laboratories: north40000 05/27/15 06:15:34 PM
#191767   VRX/ACT—FDA approves Viberzi (eluxadoline) and expands Xifaxan label DewDiligence 05/27/15 05:55:26 PM
#191766   >>expensed as R&D biomaven0 05/27/15 05:37:18 PM
#191765   Re: SNY's priority-review voucher I wonder how the DewDiligence 05/27/15 03:49:04 PM
#191764   Fibrocell (FCSC) has one they can purchase... CHM_760 05/27/15 03:43:12 PM
#191763   >> to keep a competitor from getting first biomaven0 05/27/15 03:40:33 PM
#191762   I would suggest both GILD and SNY did north40000 05/27/15 03:28:51 PM
#191761   I wonder if at some point a company ghmm 05/27/15 03:05:43 PM
#191760   ty.GREAT CAP,nice SS. also Impressive developments."Based on the ash111 05/27/15 02:39:32 PM
#191759   Mkt cap 23.10M whatisthecolorofmone 05/27/15 02:38:49 PM
#191758   Want a tip? Buy RDHL and keep it staccani 05/27/15 02:38:06 PM
#191757   looks interesting ash111 05/27/15 02:17:26 PM
#191756   >>can’t be used for Praluent (PCSK9) since the biomaven0 05/27/15 02:16:57 PM
#191755   whats the market cap ?.huge volume here ash111 05/27/15 02:10:30 PM
#191754   ABBV’s PR pertains to only one trial (GIFT-1: DewDiligence 05/27/15 12:30:51 PM
#191753   In an “indication-specific pricing” model, the per-pill cost DewDiligence 05/27/15 12:16:37 PM
#191752   From the release it sounds like the first dewophile 05/27/15 12:00:20 PM
#191751   PPV's: Its interesting how much these have gone for. ghmm 05/27/15 11:51:36 AM
#191750   Correction: The 21st Century Cures Act passed a DewDiligence 05/27/15 11:39:20 AM
#191749   Re CLLS - justrpaul 05/27/15 11:35:44 AM
#191748   $OPXA might expect mini pop-up after conference tomorrow whatisthecolorofmone 05/27/15 11:28:33 AM
#191747   Opexa Therapeutics Inc 963.8% Potential Upside Indicated by whatisthecolorofmone 05/27/15 11:20:42 AM
#191746   ABBV/ENTA also plan to apply for GT2 Japanese DewDiligence 05/27/15 11:10:45 AM
#191745   CLLS (ALCLS.PA) +10% on no news that I’m DewDiligence 05/27/15 11:04:51 AM
#191744   SNY’s priority-review voucher can’t be used for Praluent DewDiligence 05/27/15 11:02:11 AM
#191743   >>So what does Sanofi want to use this for? zipjet 05/27/15 10:54:11 AM
#191742   $245m is also way more than I had biomaven0 05/27/15 10:42:45 AM
#191741   JUNO > CAR-T powerhouse Juno allies with gene-editing biocqr 05/27/15 10:07:18 AM
#191740   ABT’s molecular diagnostics business, which is profitable, came DewDiligence 05/27/15 10:03:10 AM
#191739   Hereditary Factor X deficiency is an ultra-rare disorder DewDiligence 05/27/15 09:59:39 AM
#191738   If you notice in that first comment of biomaven0 05/27/15 09:57:03 AM
#191737   Zogenix Announces New Efficacy Data From a Long-Term shortj 05/27/15 09:27:41 AM
#191736   HALO, Roche ink collaboration for PEGPH20 companion diagnostic: DewDiligence 05/27/15 09:05:47 AM
#191735   GBIM -60% PM on failure of phase-2 HBV DewDiligence 05/27/15 09:02:25 AM
#191734   RTRX sells priority voucher zipjet 05/27/15 08:19:21 AM
#191733   Rtrx sells priority voucher http://finance.yahoo.com/news/retrophin-agrees-sel ronpopeil 05/27/15 08:02:47 AM
#191732   PCYC - stroll down memory laneFirst looked at mcbio 05/26/15 10:59:55 PM
PostSubject